Liven Pharma Ltd

Liven Pharma operates with a capital structure that is highly leveraged, as evidenced by a debt-to-equity ratio of -1.78, indicating that liabilities significantly exceed equity. The company's liquidity position is weak, with a current ratio of 0.0, suggesting it lacks sufficient short-term assets to cover its short-term obligations. The negative net income of PKR -3,059,000 and operating income of PKR -3,711,280 further highlight the company's financial distress.

Profitability metrics are severely underperforming relative to industry norms. The company's return on assets (ROA) is -2.56%, indicating that it is not generating a return on its asset base, while its return on equity (ROE) of 2.29% is also weak, especially given the negative equity position. These figures suggest that Liven Pharma is struggling to convert its investments into profits, which is a critical concern in the pharmaceutical industry where R&D and capital expenditures are typically high.

The company's geographic and segment exposure is not explicitly detailed in the available data, but the lack of segment-specific revenue breakdowns implies that it may be concentrated in a single product line or geographic market. This concentration could increase its vulnerability to market-specific risks, such as regulatory changes or competitive pressures.

Growth prospects appear limited in the near term, as the company is currently reporting negative operating and net income. There is no indication of a turnaround in the current fiscal year, and the outlook for the next fiscal year remains uncertain. The absence of positive revenue growth or margin expansion in the historical data suggests that the company may need to implement significant operational or strategic changes to improve its financial performance.

The risk assessment indicates a medium liquidity risk and a low dilution risk. However, the company's negative net cash position after subtracting total debt is a red flag, signaling potential challenges in meeting short-term obligations. The low dilution risk is likely due to the absence of recent equity issuance or convertible instruments, but the company's financial position may necessitate future dilutive actions to raise capital.

Recent events, including the latest financial filing, reveal a deteriorating financial position with declining cash flows and increasing liabilities. The operating cash flow of PKR -878,220 and free cash flow of PKR -111,480 indicate that the company is not generating sufficient cash from operations to sustain its activities. These trends suggest that the company may need to seek external financing or restructure its operations to avoid insolvency.

Liven Pharma's ROE of 2.29% exceeds the 1.73% median for Investment Holding Companies, indicating superior capital efficiency.

The company's cash conversion ratio of 0.29 is well above the 0.11 cohort median, suggesting strong operational cash generation.

Liven Pharma maintains a negative debt-to-equity ratio of -1.78, ranking as best-in-class within its investment holding cohort.

The firm reported positive free cash flow of PKR 1.45 million in FY-4, demonstrating recent cash generation capability.

Liven Pharma carries a low dilution risk flag, suggesting limited immediate threat to shareholder equity value from share issuance.

The company faces high leverage with a debt-to-equity ratio of 3.05 as of September 2025, increasing financial risk.

Liven Pharma holds a negative book value of PKR 133.8 million, indicating accumulated losses have eroded shareholder equity.